Key facts
- Gestalt’s last known valuation is $27.0M (Apr 2025).
- It has raised $14.1M; the latest was Later Stage VC ($7.5M) in Apr 2025.
- Notable investors include Cowles Ventures, Ventura Capital Management, Believe in Me Foundation, EBM Technologies, Granite Peak — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Gestalt
- ·The full record, as it builds
Funding rounds
No funding rounds for Gestalt are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gestalt
Developer of a software platform designed to bring the benefits of digital workflow to pathologists and pathology laboratories. The company provides digital pathology using advanced technology, proven digital expertise, and artificial intelligence, enabling pathologists to diagnose diseases faster and more efficiently.
- Sector
- Healthcare
- HQ
- Spokane, WA, United States
- Founded
- 2015
- Employees
- 34
- Website
- gestaltdiagnostics.com/
- Ownership
- Privately Held (backing)
Gestalt doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gestalt shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gestalt in its N-PORT filings yet. We sweep new filings monthly.